Table 1.
Training | Internal validation | External validation | |
---|---|---|---|
Patients | 818 | 167 | 125 |
Images | 1000 | 200 | 200 |
Patients with malignant masses | 500 | 100 | 88 |
Images with malignant masses | 500 | 100 | 100 |
Patients with benign masses | 346 | 68 | 39 |
Images with benign masses | 500 | 100 | 100 |
Age groups* | |||
< 30 years | 16 (2%) | 3 (2%) | 12 (6%) |
30–50 years | 431 (53%) | 93 (56%) | 91 (46%) |
≥ 50 years | 371 (45%) | 71 (43%) | 97 (49%) |
Tissue composition** | |||
Homogeneous, fat | 20 (2%) | 5 (3%) | 14 (11%) |
Homogeneous, fibroglandular | 956 (96%) | 191 (96%) | 69 (55%) |
Heterogeneous | 24 (2%) | 4 (2%) | 42 (34%) |
Lesion size** | |||
< 2 cm | 754 (75%) | 149 (75%) | 163 (82%) |
2–5 cm | 239 (24%) | 50 (25%) | 37 (19%) |
≥ 5 cm | 7 (1%) | 1 (1%) | 0 |
US machine** | |||
Phillips | 1000 (100%) | 200 (100%) | 16 (8%) |
GE | 0 | 0 | 169 (85%) |
Siemens | 0 | 0 | 15 (8%) |
*Patient-level, **image-level.